Eli Lilly said new results from a Phase 3 study of its tirzepatide showed weekly injections in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss, with nearly 99% ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

Eli Lilly (LLY) and Company announced detailed results from the Phase 3 SURMOUNT-1 three-year study, the longest completed study to date of tirzepatide. Weekly tirzepatide injections significantly ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

Wall Street is generally still bullish for Lilly and sales of tirzepatide, a drug the FDA approved as Mounjaro for diabetes .

While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its ...

These pose a health risk to the public. Sahpra cautions the public to not purchase and/or consume such products as their ...